APO RESEARCH · REPORT
Liposomes Drug Delivery
Liposomes have been used to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity. Drug distribution is then controlled primarily by properties of the carrier and no longer by physico-chemical characteristics of the drug substance only.
Product & engineering
Understand the product.
Liposomes have been used to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity. Drug distribution is then controlled primarily by properties of the carrier and no longer by physico-chemical characteristics of the drug substance only.
In a liposome drug product, the drug substance is contained in liposomes. Typically, water soluble drugs are contained in the aqueous compartment(s) and hydrophobic drugs are contained in the lipid layer(s) of the liposomes. Release of drugs from liposome formulations can be modified by the presence of polyethylene glycol and/or cholesterol or other potential additives in the liposome.
Selected research
Market Structure
Global Liposomes Drug Delivery Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
Liposomes have been used to improve the therapeutic index of new or established drugs by modifying drug absorption, reducing metabolism, prolonging biological half-life or reducing toxicity. Drug distribution is then controlled primarily by properties of the carrier and no longer by physico-chemical characteristics of the drug substance only.
In a liposome drug product, the drug substance is contained in liposomes. Typically, water soluble drugs are contained in the aqueous compartment(s) and hydrophobic drugs are contained in the lipid layer(s) of the liposomes. Release of drugs from liposome formulations can be modified by the presence of polyethylene glycol and/or cholesterol or other potential additives in the liposome.
North America dominated the market with market share of 44% due to the high medical level. Following North America, Europe is the second largest market with market share of 36%. Asian Pacific regions are the third largest market with developed countries like Japan and many developing countries like China. Its market share is about 12%.
Read the full market overview
Johnson & Johnson, Gilead Sciences, Pacira, Sun Pharmaceutical, Luye Pharma and Sigma-Tau Group are the top 6 players of Liposomes Drug Delivery, with about 77% market shares.
This report provides an overview of the global Liposomes Drug Delivery market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Liposomes Drug Delivery and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Liposomes Drug Delivery sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Liposomes Drug Delivery market size, projected growth trends, production technologies, key applications, and end-use industries.
Liposomes Drug Delivery Segment by Company
Johnson & Johnson
Gilead Sciences
Pacira
Sun Pharmaceutical
Luye Pharma
Sigma-Tau Group
Fudan-Zhangjiang
Teva Pharmaceutical
CSPC
Novartis
Kingond Pharm
Spectrum Pharmaceuticals
Shanghai New Asia
Liposomes Drug Delivery Segment by Type
Liposomal Doxorubicin
Liposomal Amphoteracin B
Liposomal Paclitaxel
Others
Liposomes Drug Delivery Segment by Application
Fungal Infection Therapy
Cancer & Tumor Therapy
Others
Liposomes Drug Delivery Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liposomes Drug Delivery market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Liposomes Drug Delivery and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liposomes Drug Delivery.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Liposomes Drug Delivery market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Liposomes Drug Delivery manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Liposomes Drug Delivery in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Liposomes Drug Delivery in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Liposomal Doxorubicin
- Liposomal Amphoteracin B
- Liposomal Paclitaxel
- Others
Applications
- Fungal Infection Therapy
- Cancer & Tumor Therapy
- Others
Companies covered
- Johnson & Johnson
- Gilead Sciences
- Pacira
- Sun Pharmaceutical
- Luye Pharma
- Sigma-Tau Group
- Fudan-Zhangjiang
- Teva Pharmaceutical
- CSPC
- Novartis
- Kingond Pharm
- Spectrum Pharmaceuticals
- Shanghai New Asia
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Liposomes Drug Delivery Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Liposomes Drug Delivery Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Liposomes Drug Delivery Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Liposomes Drug Delivery Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Liposomes Drug Delivery Market Dynamics
- 2.1 Liposomes Drug Delivery Industry Trends
- 2.2 Liposomes Drug Delivery Industry Drivers
- 2.3 Liposomes Drug Delivery Industry Opportunities and Challenges
- 2.4 Liposomes Drug Delivery Industry Restraints
3 Liposomes Drug Delivery Market by Manufacturers
- 3.1 Global Liposomes Drug Delivery Revenue by Manufacturers (2021-2026)
- 3.2 Global Liposomes Drug Delivery Sales by Manufacturers (2021-2026)
- 3.3 Global Liposomes Drug Delivery Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Liposomes Drug Delivery Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Liposomes Drug Delivery Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Liposomes Drug Delivery Manufacturers, Product Type & Application
- 3.7 Global Liposomes Drug Delivery Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Liposomes Drug Delivery Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Liposomes Drug Delivery Players Market Share by Revenue in 2025
- 3.8.3 2025 Liposomes Drug Delivery Tier 1, Tier 2, and Tier 3
4 Liposomes Drug Delivery Market by Type
- 4.1 Liposomes Drug Delivery Type Introduction
- 4.1.1 Liposomal Doxorubicin
- 4.1.2 Liposomal Amphoteracin B
- 4.1.3 Liposomal Paclitaxel
- 4.1.4 Others
- 4.2 Global Liposomes Drug Delivery Sales by Type
- 4.2.1 Global Liposomes Drug Delivery Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Liposomes Drug Delivery Sales by Type (2021-2032)
- 4.2.3 Global Liposomes Drug Delivery Sales Market Share by Type (2021-2032)
- 4.3 Global Liposomes Drug Delivery Revenue by Type
- 4.3.1 Global Liposomes Drug Delivery Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Liposomes Drug Delivery Revenue by Type (2021-2032)
- 4.3.3 Global Liposomes Drug Delivery Revenue Market Share by Type (2021-2032)
5 Liposomes Drug Delivery Market by Application
- 5.1 Liposomes Drug Delivery Application Introduction
- 5.1.1 Fungal Infection Therapy
- 5.1.2 Cancer & Tumor Therapy
- 5.1.3 Others
- 5.2 Global Liposomes Drug Delivery Sales by Application
- 5.2.1 Global Liposomes Drug Delivery Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Liposomes Drug Delivery Sales by Application (2021-2032)
- 5.2.3 Global Liposomes Drug Delivery Sales Market Share by Application (2021-2032)
- 5.3 Global Liposomes Drug Delivery Revenue by Application
- 5.3.1 Global Liposomes Drug Delivery Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Liposomes Drug Delivery Revenue by Application (2021-2032)
- 5.3.3 Global Liposomes Drug Delivery Revenue Market Share by Application (2021-2032)
6 Global Liposomes Drug Delivery Sales by Region
- 6.1 Global Liposomes Drug Delivery Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Liposomes Drug Delivery Sales by Region (2021-2032)
- 6.2.1 Global Liposomes Drug Delivery Sales by Region (2021-2026)
- 6.2.2 Global Liposomes Drug Delivery Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Liposomes Drug Delivery Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Liposomes Drug Delivery Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Liposomes Drug Delivery Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Liposomes Drug Delivery Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Liposomes Drug Delivery Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Liposomes Drug Delivery Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Liposomes Drug Delivery Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Liposomes Drug Delivery Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Liposomes Drug Delivery Revenue by Region
- 7.1 Global Liposomes Drug Delivery Revenue by Region
- 7.1.1 Global Liposomes Drug Delivery Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Liposomes Drug Delivery Revenue by Region (2021-2026)
- 7.1.3 Global Liposomes Drug Delivery Revenue by Region (2027-2032)
- 7.1.4 Global Liposomes Drug Delivery Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Liposomes Drug Delivery Revenue (2021-2032)
- 7.2.2 North America Liposomes Drug Delivery Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Liposomes Drug Delivery Revenue (2021-2032)
- 7.3.2 Europe Liposomes Drug Delivery Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Liposomes Drug Delivery Revenue (2021-2032)
- 7.4.2 Asia-Pacific Liposomes Drug Delivery Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Liposomes Drug Delivery Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Liposomes Drug Delivery Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Johnson & Johnson
- 8.1.1 Johnson & Johnson Company Information
- 8.1.2 Johnson & Johnson Business Overview
- 8.1.3 Johnson & Johnson Liposomes Drug Delivery Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Johnson & Johnson Liposomes Drug Delivery Product Portfolio
- 8.1.5 Johnson & Johnson Recent Developments
- 8.2 Gilead Sciences
- 8.2.1 Gilead Sciences Company Information
- 8.2.2 Gilead Sciences Business Overview
- 8.2.3 Gilead Sciences Liposomes Drug Delivery Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Gilead Sciences Liposomes Drug Delivery Product Portfolio
- 8.2.5 Gilead Sciences Recent Developments
- 8.3 Pacira
- 8.3.1 Pacira Company Information
- 8.3.2 Pacira Business Overview
- 8.3.3 Pacira Liposomes Drug Delivery Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Pacira Liposomes Drug Delivery Product Portfolio
- 8.3.5 Pacira Recent Developments
- 8.4 Sun Pharmaceutical
- 8.4.1 Sun Pharmaceutical Company Information
- 8.4.2 Sun Pharmaceutical Business Overview
- 8.4.3 Sun Pharmaceutical Liposomes Drug Delivery Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Sun Pharmaceutical Liposomes Drug Delivery Product Portfolio
- 8.4.5 Sun Pharmaceutical Recent Developments
- 8.5 Luye Pharma
- 8.5.1 Luye Pharma Company Information
- 8.5.2 Luye Pharma Business Overview
- 8.5.3 Luye Pharma Liposomes Drug Delivery Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Luye Pharma Liposomes Drug Delivery Product Portfolio
- 8.5.5 Luye Pharma Recent Developments
- 8.6 Sigma-Tau Group
- 8.6.1 Sigma-Tau Group Company Information
- 8.6.2 Sigma-Tau Group Business Overview
- 8.6.3 Sigma-Tau Group Liposomes Drug Delivery Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Sigma-Tau Group Liposomes Drug Delivery Product Portfolio
- 8.6.5 Sigma-Tau Group Recent Developments
- 8.7 Fudan-Zhangjiang
- 8.7.1 Fudan-Zhangjiang Company Information
- 8.7.2 Fudan-Zhangjiang Business Overview
- 8.7.3 Fudan-Zhangjiang Liposomes Drug Delivery Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Fudan-Zhangjiang Liposomes Drug Delivery Product Portfolio
- 8.7.5 Fudan-Zhangjiang Recent Developments
- 8.8 Teva Pharmaceutical
- 8.8.1 Teva Pharmaceutical Company Information
- 8.8.2 Teva Pharmaceutical Business Overview
- 8.8.3 Teva Pharmaceutical Liposomes Drug Delivery Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Teva Pharmaceutical Liposomes Drug Delivery Product Portfolio
- 8.8.5 Teva Pharmaceutical Recent Developments
- 8.9 CSPC
- 8.9.1 CSPC Company Information
- 8.9.2 CSPC Business Overview
- 8.9.3 CSPC Liposomes Drug Delivery Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 CSPC Liposomes Drug Delivery Product Portfolio
- 8.9.5 CSPC Recent Developments
- 8.10 Novartis
- 8.10.1 Novartis Company Information
- 8.10.2 Novartis Business Overview
- 8.10.3 Novartis Liposomes Drug Delivery Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Novartis Liposomes Drug Delivery Product Portfolio
- 8.10.5 Novartis Recent Developments
- 8.11 Kingond Pharm
- 8.11.1 Kingond Pharm Company Information
- 8.11.2 Kingond Pharm Business Overview
- 8.11.3 Kingond Pharm Liposomes Drug Delivery Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Kingond Pharm Liposomes Drug Delivery Product Portfolio
- 8.11.5 Kingond Pharm Recent Developments
- 8.12 Spectrum Pharmaceuticals
- 8.12.1 Spectrum Pharmaceuticals Company Information
- 8.12.2 Spectrum Pharmaceuticals Business Overview
- 8.12.3 Spectrum Pharmaceuticals Liposomes Drug Delivery Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Spectrum Pharmaceuticals Liposomes Drug Delivery Product Portfolio
- 8.12.5 Spectrum Pharmaceuticals Recent Developments
- 8.13 Shanghai New Asia
- 8.13.1 Shanghai New Asia Company Information
- 8.13.2 Shanghai New Asia Business Overview
- 8.13.3 Shanghai New Asia Liposomes Drug Delivery Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Shanghai New Asia Liposomes Drug Delivery Product Portfolio
- 8.13.5 Shanghai New Asia Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Liposomes Drug Delivery Value Chain Analysis
- 9.1.1 Liposomes Drug Delivery Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Liposomes Drug Delivery Production Mode & Process
- 9.2 Liposomes Drug Delivery Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Liposomes Drug Delivery Distributors
- 9.2.3 Liposomes Drug Delivery Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst